hbm4003
mAbexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 24, 2019 (NCT04135261)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05167071 | Phase 1 | Jan 20, 2022 | Harbour BioMed Co. Ltd., Peking University |
| NCT05149027 | Phase 1 | Dec 20, 2021 | Harbour BioMed Co. Ltd., Tianjin Medical University |
| NCT04866485 | Phase 1 | Jun 14, 2021 | Harbour BioMed Co. Ltd., Jiao Tong University |
| NCT04727164 | Phase 1 | Feb 28, 2021 | Chinese Academy of Medical Sciences, Harbour BioMed Co. Ltd. |
| NCT04135261 | Phase 1 | Sep 24, 2019 | Harbour BioMed Co. Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harbour BioMed Co. Ltd. | For profit | 5 | 5 | 1 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1